Avenanthramide CCAS# 116764-15-9 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 116764-15-9 | SDF | Download SDF |
PubChem ID | 11723200.0 | Appearance | Powder |
Formula | C16H13NO6 | M.Wt | 315.28 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 2-[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]amino]-5-hydroxybenzoic acid | ||
SMILES | C1=CC(=C(C=C1C=CC(=O)NC2=C(C=C(C=C2)O)C(=O)O)O)O | ||
Standard InChIKey | IDUUXROOZBOOPH-QHHAFSJGSA-N | ||
Standard InChI | InChI=1S/C16H13NO6/c18-10-3-4-12(11(8-10)16(22)23)17-15(21)6-2-9-1-5-13(19)14(20)7-9/h1-8,18-20H,(H,17,21)(H,22,23)/b6-2+ | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Avenanthramide C Dilution Calculator
Avenanthramide C Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.1718 mL | 15.8589 mL | 31.7178 mL | 63.4357 mL | 79.2946 mL |
5 mM | 0.6344 mL | 3.1718 mL | 6.3436 mL | 12.6871 mL | 15.8589 mL |
10 mM | 0.3172 mL | 1.5859 mL | 3.1718 mL | 6.3436 mL | 7.9295 mL |
50 mM | 0.0634 mL | 0.3172 mL | 0.6344 mL | 1.2687 mL | 1.5859 mL |
100 mM | 0.0317 mL | 0.1586 mL | 0.3172 mL | 0.6344 mL | 0.7929 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Pseudoginsenoside Rh1
Catalog No.:BCX1076
CAS No.:97744-96-2
- γ-Tocopherol
Catalog No.:BCX1075
CAS No.:54-28-4
- Momilacton A
Catalog No.:BCX1074
CAS No.:51415-07-7
- Momilacton B
Catalog No.:BCX1073
CAS No.:51415-08-8
- Prunetinoside
Catalog No.:BCX1072
CAS No.:89595-66-4
- Stachyanthuside A
Catalog No.:BCX1071
CAS No.:864779-30-6
- 2-O-α-D-Glucopyranosyl-L-ascorbic acid
Catalog No.:BCX1070
CAS No.:129499-78-1
- Tamarixetin-3-O-rutinoside
Catalog No.:BCX1069
CAS No.:20550-05-4
- trans-p-Coumaric acid 4-O-β-D-glucopyranoside
Catalog No.:BCX1068
CAS No.:117405-49-9
- Cochinchinenin A
Catalog No.:BCX1067
CAS No.:1057666-04-2
- Resveratrol 12-C-β-glucopyranoside
Catalog No.:BCX1066
CAS No.:163527-00-2
- Crocetine dimethyl ester
Catalog No.:BCX1065
CAS No.:5892-54-6
- 6-Methoxyldihydrochelerythrine chloride
Catalog No.:BCX1078
CAS No.:1071676-04-4
- 4-Deoxy-4α-phorbol
Catalog No.:BCX1079
CAS No.:37415-57-9
- Rhamnetin 3-O-rutinoside
Catalog No.:BCX1080
CAS No.:34202-83-0
- Pseudostellarin B
Catalog No.:BCX1081
CAS No.:156430-21-6
- 6-Iodo Diosmin
Catalog No.:BCX1082
CAS No.:1431536-92-3
- 6'-Sialyllactose Sodium Salt
Catalog No.:BCX1083
CAS No.:157574-76-0
- 3'-Sialyllactose Sodium Salt
Catalog No.:BCX1084
CAS No.:128596-80-5
- Indican
Catalog No.:BCX1085
CAS No.:487-60-5
- Kuwanon W
Catalog No.:BCX1086
CAS No.:95518-95-9
- Avenanthramide E
Catalog No.:BCX1087
CAS No.:93755-77-2
- 4'-O-methyl-Neochlorogenic acid
Catalog No.:BCX1088
CAS No.:1234369-77-7
- 4'-O-methyl-Chlorogenic acid
Catalog No.:BCX1089
CAS No.:57496-29-4
Effect of Germination on the Avenanthramide Content of Oats and Their in Vitro Antisensitivity Activities.[Pubmed:36234703]
Molecules. 2022 Sep 20;27(19):6167.
In this study, a method, based on an ultraperformance liquid chromatography coupled with high-field quadrupole orbitrap high-resolution mass spectrometry (UHPLC-QE-HF-HRMS) platform, was established for the trace determination of three major avenanthramides (AVNs). The MS conditions for determining the AVNs were optimized, and the cracking methods of avenanthramides were analyzed. The linear range of the results and the correlation coefficient were 1-2000 mug/L and >0.996, respectively. Further, the established method was employed for the determination of the AVN contents of oats at different germination times, and the results indicated that the AVN contents of Zaohua and Bayou oats increased 19.26 and 6.09 times, respectively, after germination. The total AVN content of both oat varieties reached a maximum on the fifth day of germination (153.51 +/- 4.08 and 126.30 +/- 3.33 mug/g for the Zaohua and Bayou oats, respectively). Furthermore, this study investigated the antiallergic and antioxidant activities of the germinated oats via hyaluronidase inhibition and 2,2-diphenyl-1-picrylhydrazyl (DPPH)-scavenging assays. The antiallergic and DPPH-scavenging abilities of the ungerminated forms of both oat varieties were weaker. However, on the fifth day of germination, the inhibition rate of anthranilamide hyaluronidase reached 72.7% and 67.3% for the Zaohua and Bayou oat varieties, respectively. The antiallergic abilities of the oats increased significantly on the fifth day of germination in terms of their antiallergic capacities and DPPH clearance (82.67% and 77.64% for the Zaohua and Bayou oats, respectively), and the two indicators exhibited similar trends. These findings demonstrated that AVNs exhibit good antisensitivity and antioxidation properties, and the antisensitivity effect correlated positively with the AVN content.
Ignored role of polyphenol in boosting reactive oxygen species generation for polyphenol/chemodynamic combination therapy.[Pubmed:36176720]
Mater Today Bio. 2022 Sep 20;16:100436.
Chemodynamic therapy (CDT) is a promising tumor-specific treatment, but still suffering insufficient reactive oxygen species (ROS) levels due to its limited efficacy of Fenton/Fenton-like reaction. Polyphenol, as a natural reductant, has been applied to promote the efficacy of Fenton/Fenton-like reactions; however, its intrinsic pro-apoptosis effects was ignored. Herein, a novel CDT/polyphenol-combined strategy was designed, based on Avenanthramide C-loaded dendritic mesoporous silica (DMSN)-Au/Fe(3)O(4) nanoplatforms with folic acid modification for tumor-site targeting. For the first time, we showed that the nanocomplex (DMSNAF-AVC-FA) induced ROS production in the cytoplasm via Au/Fe(3)O(4)-mediated Fenton reactions and externally damaged the mitochondrial membrane; simultaneously, the resultant increased mitochondrial membrane permeability can facilitate the migration of AVC into mitochondrial, targeting the DDX3 pathway and impairing the electron transport chain (ETC) complexes, which significantly boosted the endogenous ROS levels inside the mitochondrial. Under the elevated oxidative stress level via both intra- and extra-mitochondrial ROS production, the maximum mitochondrial membrane permeability was achieved by up-regulation of Bax/Bcl-2, and thereby led to massive release of Cytochrome C and maximum tumor cell apoptosis via Caspase-3 pathway. As a result, the as-designed strategy achieved synergistic cytotoxicity to 4T1 tumor cells with the cell apoptosis rate of 99.12% in vitro and the tumor growth inhibition rate of 63.3% in vivo, while very minor cytotoxicity to normal cells with cell viability of 95.4%. This work evidenced that natural bioactive compounds are powerful for synergistically boosting ROS level, providing new insight for accelerating the clinical conversion progress of CDT with minimal side effects.